Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo

BACKGROUND: The MEK1/2 inhibitor selumetinib was recently approved for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, but outcomes could be improved and its pharmacodynamic evaluation in other relevant tissues is limited. The aim of this study was to assess selumetinib tissue pha...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neurooncol Adv
Egile Nagusiak: Osum, Sara H, Coutts, Alexander W, Duerre, Dylan J, Tschida, Barbara R, Kirstein, Mark N, Fisher, James, Bell, W Robert, Delpuech, Oona, Smith, Paul D, Widemann, Brigitte C, Moertel, Christopher L, Largaespada, David A, Watson, Adrienne L
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2021
Gaiak:
Basic and Translational Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095338/
https://ncbi.nlm.nih.gov/pubmed/33978635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdab020
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak